There are many new challenges facing those involved in the manufacture of biopharmaceuticals. Whereas in the past, overall process efficiency was sometimes treated as an afterthought as companies tried to get to market as quickly as possible, the production costs of biopharmaceuticals are now, receiving greater attention which is spurring interest in continuous bioprocessing. The loss of patent protection from blockbuster drugs is creating a market for biosimilars in which being able to compete effectively requires low prices underpinned by low manufacturing costs. Click Here For Complete Article Text
|
||||||||||||||||||
Application Sequencing | ||||||||||||||||||
|
||||||||||||||||||
Company | Product | Process | Other Subjects | Event | Event Date | Location | Publication | Publication Date | Text Descriptor | |||||||||
|
|
|
|
|
|
|